Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

NCT02280993 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Lymphoma
Refractory
Relapse

Interventions

DRUG: DHAP
DRUG: Brentuximab Vedotin
OTHER: Autologous Peripheral Blood Stem Cell Transplantation

Sponsor

Marjolein Spiering

Collaborators

[object Object]